Schreiber, A.R.; Kagihara, J.A.; Corr, B.R.; Davis, S.L.; Lieu, C.; Kim, S.S.; Jimeno, A.; Camidge, D.R.; Williams, J.; Heim, A.M.;
et al. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers 2024, 16, 91.
https://doi.org/10.3390/cancers16010091
AMA Style
Schreiber AR, Kagihara JA, Corr BR, Davis SL, Lieu C, Kim SS, Jimeno A, Camidge DR, Williams J, Heim AM,
et al. First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers. 2024; 16(1):91.
https://doi.org/10.3390/cancers16010091
Chicago/Turabian Style
Schreiber, Anna R., Jodi A. Kagihara, Bradley R. Corr, S. Lindsey Davis, Christopher Lieu, Sunnie S. Kim, Antonio Jimeno, D. Ross Camidge, Jud Williams, Amy M. Heim,
and et al. 2024. "First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors" Cancers 16, no. 1: 91.
https://doi.org/10.3390/cancers16010091
APA Style
Schreiber, A. R., Kagihara, J. A., Corr, B. R., Davis, S. L., Lieu, C., Kim, S. S., Jimeno, A., Camidge, D. R., Williams, J., Heim, A. M., Martin, A., DeMattei, J. A., Holay, N., Triplett, T. A., Eckhardt, S. G., Litwiler, K., Winkler, J., Piscopio, A. D., & Diamond, J. R.
(2024). First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors. Cancers, 16(1), 91.
https://doi.org/10.3390/cancers16010091
